Secured another project under the Ministry of Industry and Information Technology’s “Challenge-based Recruitment” initiative.

Relying on its groundbreaking achievements and high level of innovation in the development and industrialization of “nano-hydroxyapatite” within the field of inorganic non-metallic materials, Dingan Technology has once again been selected as the lead entity for an innovative project under the “Challenge‑Based Innovation” initiative. This recognition underscores Dingan Technology’s continued national‑level validation of its technical prowess and innovative capabilities in the biomedical materials sector.

2025

11-04

The national key special project has successfully passed acceptance.

Dingan Technology, as a key participating institution, has successfully completed the national key R&D program titled “Engineering and Clinical Application of a Novel Injectable Nanobiomaterial for the Prevention and Treatment of Osteoporosis.” The project focuses on the development of an injectable nano‑biomaterial designed to be delivered via minimally invasive procedures directly into specific sites within bone, thereby stimulating the body’s natural osteogenic processes, promoting bone repair and strengthening, and helping to prevent fragility fractures. By guiding the directional deposition of calcium in bone and enhancing the synthesis of bone matrix proteins, this material holds promise for significantly reducing the risk of fractures.

2025

11-04

Receives ISO 13485 certification again

Dingan Technology has long been committed to the industrialization of critical raw materials, core technologies, and innovative products within the high-end surgical implant device industry chain. The company operates R&D and production facilities for products including “composite ceramic femoral heads,” “zirconia blocks for all-ceramic dentures,” “bioactive materials and high-end bone implants,” and “fillers for medical aesthetic minimally invasive procedures.” It holds manufacturing licenses for “Class III 6846 Implantable Materials and Artificial Organs” and “Class II 17-06 Dental Prosthetic Materials,” and in December 2024, it was further awarded ISO 13485 certification for its medical device quality management system.

2025

11-04

Suzhou Dingan Technology Co., Ltd. has successfully obtained provincial high-tech enterprise certification.

Warm congratulations to Suzhou Dingan Technology Co., Ltd. on successfully obtaining provincial high-tech enterprise certification…

2025

05-23

National-Level Expert Workstation

The “National-Level Expert” Workstation of Wujiang District was established in accordance with the Wujiang Municipal Government Office’s policy on rewarding and funding innovative science and technology talents introduced to Wujiang City in 2012...

2025

06-06

Suzhou Dingan Technology Co., Ltd. has established the Suzhou Postdoctoral…

In order to thoroughly implement the innovation-driven and talent-first development strategies and better leverage the role of postdoctoral research platforms in enterprises’ innovative development...

2025

06-13

Chunli Medical places great emphasis on the development and widespread adoption of high-end orthopedic implant devices.

Chunli Medical places great emphasis on the development and clinical application of high‑end orthopedic implant devices. It has established a long‑term collaborative partnership with Suzhou Ding’an Technology Co., Ltd. and jointly founded the “Joint Laboratory for the Engineering Application of Biomedical Ceramics.” Leveraging the pressing clinical needs for advanced orthopedic implants—such as bone defect‑filling and repair materials—and its own proprietary core technologies, the company has undertaken preliminary explorations into the engineering applications of key technologies related to the in situ synthesis of BCP micro‑ and nanoscale powders, as well as fundamental research on the physicochemical properties and biocompatibility of these synthesized materials. These efforts have helped address several engineering challenges in the industrialization of high‑end orthopedic implant devices, including bioactive ceramic artificial bones.

2025

11-04

< 1 >